Unit:
Κατεύθυνση Κλινική Βιοχημεία - Μοριακή ΔιαγνωστικήLibrary of the School of Science
Supervisors info:
ΔΙΔΩ ΒΑΣΙΛΑΚΟΠΟΥΛΟΥ, ΑΝΑΠΛΗΡΩΤΡΙΑ ΚΑΘΗΓΗΤΡΙΑ, ΤΜΗΜΑ ΒΙΟΛΟΓΙΑΣ, Ε. Κ . Π. Α
ΔΙΑΜΑΝΤΗΣ ΣΙΔΕΡΗΣ, ΑΝΑΠΛΗΡΩΤΗΣ ΚΑΘΗΓΗΤΗΣ, ΤΜΗΜΑ ΒΙΟΛΟΓΙΑΣ, Ε. Κ. Π. Α
ΑΝΔΡΕΑΣ ΣΚΟΡΙΛΑΣ, ΚΑΘΗΓΗΤΗΣ, ΤΜΗΜΑ ΒΙΟΛΟΓΙΑΣ, Ε. Κ. Π. Α.
Original Title:
ΜΕΛΕΤΗ ΜΟΡΙΑΚΩΝ ΜΗΧΑΝΙΣΜΩΝ ΝΕΥΡΟΕΚΦΥΛΙΣΜΟΥ
Translated title:
MOLECULAR MECHANISMS OF NEURODEGENERATION
Summary:
L- Dopa Decarboxylase (DDC) is a pyridoxal 5-phosphate (PLP)-dependent enzyme that catalyses the decarboxylation of L- Dopa to dopamine. Alternative splicing events lead to the production of multiple human DDC isoforms. DDC has been implicated in many pathological conditions, such as multiple neoplasias and neurodegenerative disorders. The Αβ peptide of Alzheimer’s disease is derived from the proteolytic processing of the amyloid precursor proteins (APP), which are considered type I transmembrane glycoproteins. Aβ plaque formation is thought as one of the main causes for the development of AD. Several lines of evidence suggest the existence of common shared molecular mechanisms in the development of AD and PD. The aim of our work was to study the effect of human DDC isoforms expression on the proteolytic processing of APP. For this reason we employed Chinese hamster ovary cells stably expressing different human DDC isoforms (DDC-3, alt-DDC). Our results indicated full length APP expression was diffentialy affected by DDC isoforms. Furthermore, APP proteolytic processing appear to be altered in the presence of full length and truncated DDC isoforms. Our findings suggest a possible role of DDC isoforms in the amyloidogenic processing of APP and propose a new role of the Dopamine synthesizing enzyme in AD.
Main subject category:
Science
Other subject categories:
Health Sciences
Keywords:
Neurodegenerative diseases, L- DOPA decarboxylase (DDC), Alzheimer Disease (AD), Parkinson Disease (PD), Amyloid Precursor Protein (APP)
Number of references:
319
